keyword
https://read.qxmd.com/read/38547427/disease-modifying-treatments-for-multiple-sclerosis-affect-measures-of-cellular-immune-responses-to-ebna-1-peptides
#1
JOURNAL ARTICLE
Lara Dungan, Jean Dunne, Michael Savio, Marianna Kalaszi, Matt McElheron, Yvonne Lynagh, Kate O'Driscoll, Carmel Roche, Ammara Qureshi, Brendan Crowley, Niall Conlon, Hugh Kearney
BACKGROUND AND OBJECTIVES: Epstein-Barr virus (EBV) has been strongly implicated in the pathogenesis of multiple sclerosis (MS). Despite this, there are no routinely used tests to measure cellular response to EBV. In this study, we analyzed the cellular response to EBV nuclear antigen-1 (EBNA-1) in people with MS (pwMS) using a whole blood assay. METHODS: This cross-sectional study took place in a dedicated MS clinic in a university hospital. We recruited healthy controls, people with epilepsy (PWE), and pwMS taking a range of disease-modifying treatments (DMTs) including natalizumab, anti-CD20 monoclonal antibodies (mAbs), dimethyl fumarate (DMF), and also treatment naïve...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38529711/real-world-healthcare-cost-savings-and-reduced-relapse-rate-with-off-label-rituximab-versus-disease-modifying-treatments-approved-for-relapsing-remitting-multiple-sclerosis-a-nationwide-cost-effectiveness-study
#2
JOURNAL ARTICLE
Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
OBJECTIVE: Although off-label use of rituximab is a common alternative to disease-modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost-effectiveness is not well known. METHODS: We evaluated the relative cost-effectiveness of rituximab and MS-approved DMTs in a register-based cohort study of Swedish residents with relapsing-remitting MS, aged 18-65 years, starting treatment with rituximab, natalizumab, fingolimod, or dimethyl fumarate between January 2010 and July 2016, and followed through July 2021 (n = 5,924)...
March 26, 2024: Annals of Neurology
https://read.qxmd.com/read/38525954/dimethyl-fumarate-associated-enterocolitis
#3
JOURNAL ARTICLE
Numra A Bajwa, Azka A Bajwa, Seham Ghazala, Umair Masood
No abstract text is available yet for this article.
March 20, 2024: American Journal of Therapeutics
https://read.qxmd.com/read/38520948/burden-of-treatment-and-quality-of-life-in-relapsing-remitting-multiple-sclerosis-patients-under-early-high-efficacy-therapy-in-argentina-data-from-the-argentinean-registry
#4
JOURNAL ARTICLE
Juan I Rojas, Edgar Carnero Contentti, Ricardo Alonso, Dario Tavolini, Marcos Burgos, Belén Federico, Liliana Patrucco, Edgardo Cristiano
UNLABELLED: The objective of this study was to describe and compare the burden of treatment (BOT) and the quality of life (QoL) in early high efficacy therapy (HET) vs. escalation therapy in relapsing remitting multiple sclerosis (RRMS) patients included in RelevarEM, the Argentinean registry of MS (RelevarEM, NCT 03,375,177). METHODS: cross sectional study conducted between September and December 2022. Participating patients were adults, RRMS patients who initiated (during the last three years) their treatment with a HET (natalizumab, ocrelizumab, alemtuzumab, cladribine) or with escalation treatment (beta interferon, glatiramer acetate, teriflunomide, dimethyl fumarate or fingolimod)...
March 16, 2024: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/38517926/incidence-of-type-2-diabetes-cardiovascular-disease-and-chronic-kidney-disease-in-patients-with-multiple-sclerosis-initiating-disease-modifying-therapies-retrospective-cohort-study-using-a-frequentist-model-averaging-statistical-framework
#5
JOURNAL ARTICLE
Alan J M Brnabic, Sarah E Curtis, Joseph A Johnston, Albert Lo, Anthony J Zagar, Ilya Lipkovich, Zbigniew Kadziola, Megan H Murray, Timothy Ryan
Researchers are increasingly using insights derived from large-scale, electronic healthcare data to inform drug development and provide human validation of novel treatment pathways and aid in drug repurposing/repositioning. The objective of this study was to determine whether treatment of patients with multiple sclerosis with dimethyl fumarate, an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, results in a change in incidence of type 2 diabetes and its complications. This retrospective cohort study used administrative claims data to derive four cohorts of adults with multiple sclerosis initiating dimethyl fumarate, teriflunomide, glatiramer acetate or fingolimod between January 2013 and December 2018...
2024: PloS One
https://read.qxmd.com/read/38512652/neuroprotective-effects-of-rutin-against-cuprizone-induced-multiple-sclerosis-in-mice
#6
JOURNAL ARTICLE
Mariam A Nicola, Abdelraheim H Attaai, Mahmoud H Abdel-Raheem, Anber F Mohammed, Yasmin F Abu-Elhassan
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system that injures the myelin sheath, provoking progressive axonal degeneration and functional impairments. No efficient therapy is available at present to combat such insults, and hence, novel safe and effective alternatives for MS therapy are extremely required. Rutin (RUT) is a flavonoid that exhibits antioxidant, anti-inflammatory, and neuroprotective effects in several brain injuries. The present study evaluated the potential beneficial effects of two doses of RUT in a model of pattern-III lesion of MS, in comparison to the conventional standard drug; dimethyl fumarate (DMF)...
March 21, 2024: Inflammopharmacology
https://read.qxmd.com/read/38502339/radiologically-isolated-syndromes-to-treat-or-not-to-treat
#7
REVIEW
Paolo Preziosa, Maria A Rocca, Massimo Filippi
The widespread use of magnetic resonance imaging (MRI) has led to increased detection of individuals exhibiting asymptomatic brain and spinal cord lesions suggestive of multiple sclerosis (MS), defined as "radiologically isolated syndrome" (RIS). Specific criteria have been proposed and updated over time to identify individuals with RIS. Moreover, a younger age, the presence of infratentorial, spinal cord or gadolinium-enhancing lesions, as well as of cerebrospinal fluid-specific oligoclonal bands have been recognized as relevant risk factors for the occurrence of a first clinical event...
March 19, 2024: Journal of Neurology
https://read.qxmd.com/read/38496034/self-adaptive-pyroptosis-responsive-nanoliposomes-block-pyroptosis-in-autoimmune-inflammatory-diseases
#8
JOURNAL ARTICLE
Kaiwang Xu, Huang Yang, Jinghua Fang, Kaijie Qiu, Haotian Shen, Guanrui Huang, Qiangqiang Zheng, Canlong Wang, Tengjing Xu, Xinning Yu, Jiajie Wang, Yunting Lin, Jiacheng Dai, Yuting Zhong, Hongyun Song, Sunan Zhu, Siheng Wang, Zhuxing Zhou, Guang Yang, Zhengwei Mao, Zongyou Pan, Xuesong Dai
Nanoliposomes have a broad range of applications in the treatment of autoimmune inflammatory diseases because of their ability to considerably enhance drug transport. For their clinical application, nanoliposomes must be able to realize on-demand release of drugs at disease sites to maximize drug-delivery efficacy and minimize side effects. Therefore, responsive drug-release strategies for inflammation treatment have been explored; however, no specific design has been realized for a responsive drug-delivery system based on pyroptosis-related inflammation...
June 2024: Bioactive Materials
https://read.qxmd.com/read/38494482/disrupting-pro-survival-and-inflammatory-pathways-with-dimethyl-fumarate-sensitizes-chronic-lymphocytic-leukemia-to-cell-death
#9
JOURNAL ARTICLE
Maria Elena Mantione, Miriam Meloni, Ilenia Sana, Jessica Bordini, Martina Del Nero, Michela Riba, Pamela Ranghetti, Eleonora Perotta, Paolo Ghia, Lydia Scarfò, Marta Muzio
Microenvironmental signals strongly influence chronic lymphocytic leukemia (CLL) cells through the activation of distinct membrane receptors, such as B-cell receptors, and inflammatory receptors, such as Toll-like receptors (TLRs). Inflammatory pathways downstream of these receptors lead to NF-κB activation, thus protecting leukemic cells from apoptosis. Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory drug used to treat patients with multiple sclerosis and psoriasis in which it blocks aberrant NF-κB pathways and impacts the NRF2 antioxidant circuit...
March 18, 2024: Cell Death & Disease
https://read.qxmd.com/read/38482062/bio-based-unsaturated-polyester-resin-from-post-consumer-pet
#10
JOURNAL ARTICLE
David Rubeš, Jaromír Vinklárek, Štěpán Podzimek, Jan Honzíček
This study explores the utilization of post-consumer poly(ethylene terephthalate) (PET) as a material in the synthesis of styrene-free unsaturated polyester (UP) resin. The process involves glycolysis of PET waste with diethylene glycol and condensation polymerization with bio-based itaconic acid. The resulting unsaturated polyester possesses reactive methylidene functions that, in contrast to commonly employed fumarates/maleates, facilitate copolymerization with non-styrene reactive diluents. To formulate the resins, methacrylates and itaconates were used for dilution, and the curing process is achieved through a redox initiation system at room temperature, followed by post-curing at elevated temperatures...
March 6, 2024: RSC Advances
https://read.qxmd.com/read/38472616/intraarticular-monomethyl-fumarate-as-a-perspective-therapy-for-osteoarthritis-by-macrophage-polarization
#11
JOURNAL ARTICLE
Douglas Menezes de Souza, Kauê Franco Malange, Catarine Massucato Nishijima, Bruno Henrique de Melo Lima, Vinicius Cooper Capetini, Alexandre L R de Oliveira, Gabriel Forato Anhê, Claudia Herrera Tambeli, Carlos Amilcar Parada
BACKGROUND: Osteoarthritis (OA) is a chronic disease that may lead to joint structure degeneration, cartilage destruction, osteophyte formation, subchondral bone disruption, and pain. In this scenario, a higher proportion of the proinflammatory macrophage type 1 (M1) than the anti-inflammatory macrophage type 2 (M2) could be highlighted as a hallmark of OA progression. The balance between these two macrophage types emerges as a new therapeutic target in OA. This study aimed to evaluate the analgesia and macrophage profile in the treatment of experimental osteoarthritis (EOA) with systemic dimethyl fumarate (DMF) or local intra-articular monomethyl fumarate (MMF)...
March 13, 2024: Inflammopharmacology
https://read.qxmd.com/read/38461632/distinct-disease-modifying-therapies-are-associated-with-different-blood-immune-cell-profiles-in-people-with-relapsing-remitting-multiple-sclerosis
#12
JOURNAL ARTICLE
João Canto-Gomes, Daniela Boleixa, Catarina Teixeira, Ana Martins da Silva, Inés González-Suárez, João Cerqueira, Margarida Correia-Neves, Claudia Nobrega
Disease modifying therapies (DMTs) used for treating people with relapsing-remitting multiple sclerosis (pwRRMS) target the immune system by different mechanisms of action. However, there is a lack of a comprehensive assessment of their effects on the immune system in comparison to treatment-naïve pwRRMS. Herein, we evaluated the numbers of circulating B cells, CD4+ and CD8+ T cells, regulatory T cells (Tregs), natural killer (NK) cells and NKT cells, and their subsets, in pwRRMS who were treatment-naïve or treated with different DMTs...
March 9, 2024: International Immunopharmacology
https://read.qxmd.com/read/38459716/iatrogenic-myelodysplastic-syndrome-complicating-multiple-sclerosis-a-case-report
#13
JOURNAL ARTICLE
Konrad Kubicki, Dusan Stefoski
After 1.5 years of treatment with dimethyl fumarate (DMF) for multiple sclerosis, preceded 8 years earlier by intravenous (IV) cladribine and 1 year earlier by natalizumab, our patient developed myelodysplastic syndrome (MDS). The initial manifestation was a severe drop in absolute neutrophil and lymphocyte counts. Repeat bone marrow biopsy demonstrated a new unbalanced translocation (between the chromosome 1 long arm and chromosome 7 short arm). This case report, to our knowledge, is the first linking iatrogenic MDS to DMF and cladribine, while also suggesting caution with immunosuppressants in multiple sclerosis patients...
March 8, 2024: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/38449051/prospective-study-validating-a-multidimensional-treatment-decision-score-predicting-the-24-month-outcome-in-untreated-patients-with-clinically-isolated-syndrome-and-early-relapsing-remitting-multiple-sclerosis-the-proval-ms-study
#14
JOURNAL ARTICLE
Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S Hoffmann, Achim Berthele, Mark Mühlau, Markus C Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, Markus Naumann, Julia Hartberger, Martin Kerschensteiner, Eva Oswald, Christoph Ruschil, Ulf Ziemann, Hayrettin Tumani, Ioannis Vardakas, Fady Albashiti, Frank Kramer, Iñaki Soto-Rey, Helmut Spengler, Gerhard Mayer, Hans Armin Kestler, Oliver Kohlbacher, Marlien Hagedorn, Martin Boeker, Klaus Kuhn, Stefan Buchka, Florian Kohlmayer, Jan S Kirschke, Lars Behrens, Hanna Zimmermann, Benjamin Bender, Nico Sollmann, Joachim Havla, Bernhard Hemmer
INTRODUCTION: In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking. Cohort studies allow a close follow-up of MS histories and a thorough phenotyping of patients. Therefore, a multicenter cohort study was initiated to implement a wide spectrum of data and (bio)markers in newly diagnosed patients. METHODS: ProVal-MS (Prospective study to validate a multidimensional decision score that predicts treatment outcome at 24 months in untreated patients with clinically isolated syndrome or early Relapsing-Remitting-MS) is a prospective cohort study in patients with clinically isolated syndrome (CIS) or Relapsing-Remitting (RR)-MS (McDonald 2017 criteria), diagnosed within the last two years, conducted at five academic centers in Southern Germany...
March 7, 2024: Neurological research and practice
https://read.qxmd.com/read/38437197/psychometric-evaluation-of-the-5-item-medication-adherence-report-scale-questionnaire-in-persons-with-multiple-sclerosis
#15
JOURNAL ARTICLE
Maj Jožef, Igor Locatelli, Gregor Brecl Jakob, Lina Savšek, Katarina Šurlan Popovič, Žiga Špiclin, Uroš Rot, Mitja Kos
The 5-item Medication Adherence Report Scale (MARS-5) is a reliable and valid questionnaire for evaluating adherence in patients with asthma, hypertension, and diabetes. Validity has not been determined in multiple sclerosis (MS). We aimed to establish criterion validity and reliability of the MARS-5 in persons with MS (PwMS). Our prospective study included PwMS on dimethyl fumarate (DMF). PwMS self-completed the MARS-5 on the same day before baseline and follow-up brain magnetic resonance imaging (MRI) 3 and 9 months after treatment initiation and were graded as highly and medium adherent upon the 24-cut-off score, established by receiver operator curve analysis...
2024: PloS One
https://read.qxmd.com/read/38434464/frequency-of-dimethyl-fumarate-induced-lymphopenia-among-omani-patients-with-multiple-sclerosis
#16
JOURNAL ARTICLE
Ahmed Jaboob, Abdullah Al Asmi, M Mazharul Islam, Syed Rezvi, Iman Redha, Jaber Al-Khabouri, Ibrahim Al-Zakwani, Ahmed Al-Qassabi, Haifa Al-Abri, Arunodaya R Gujjar
OBJECTIVES: Dimethyl fumarate (DMF) is known to cause lymphopenia when used to treat patients with multiple sclerosis (MS). However, research on DMF therapy in the Arab world, especially in Oman, is scarce. This study aimed to analyse the prevalence of lymphopenia among Omani patients with MS and their reasons for discontinuing DMF therapy. METHODS: In this retrospective study, the medical records of Omani patients with MS who were treated using DMF at two tertiary hospitals in Muscat, Oman, from February 2017 to February 2023 were reviewed...
February 2024: Sultan Qaboos University Medical Journal
https://read.qxmd.com/read/38434405/knowledge-domain-and-trend-of-disease-modifying-therapies-for-multiple-sclerosis-a-study-based-on-citespace
#17
REVIEW
Ting Zheng, Taotao Jiang, Zilong Huang, Manxia Wang
OBJECTIVE: To explore the current status and trends of disease-modifying therapies (DMTs) for multiple sclerosis through bibliometric and visual analyses of the related literature. METHODS: Relevant literature from the Web of Science Core Collection from 2017 to 2022 was retrieved, and a bibliometric analysis was performed using CiteSpace 6.1. R2. Thesoftware was used to generate visual graphs of the author, institution, country, keyword co-occurrence, and literature co-citation network...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38430538/remodeling-of-the-intra-conduit-inflammatory-microenvironment-to-improve-peripheral-nerve-regeneration-with-a-neuromechanical-matching-protein-based-conduit
#18
JOURNAL ARTICLE
Jia-Yi Wang, Ya Yuan, Shu-Yan Zhang, Shun-Yi Lu, Guan-Jie Han, Meng-Xuan Bian, Lei Huang, De-Hua Meng, Di-Han Su, Lan Xiao, Yin Xiao, Jian Zhang, Ning-Ji Gong, Li-Bo Jiang
Peripheral nerve injury (PNI) remains a challenging area in regenerative medicine. Nerve guide conduit (NGC) transplantation is a common treatment for PNI, but the prognosis of NGC treatment is unsatisfactory due to 1) neuromechanical unmatching and 2) the intra-conduit inflammatory microenvironment (IME) resulting from Schwann cell pyroptosis and inflammatory-polarized macrophages. A neuromechanically matched NGC composed of regenerated silk fibroin (RSF) loaded with poly(3,4-ethylenedioxythiophene): poly(styrene sulfonate) (P:P) and dimethyl fumarate (DMF) are designed, which exhibits a matched elastic modulus (25...
March 2, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38430351/diverse-efficacy-of-dimethyl-fumarate-in-alleviating-the-late-streptozotocin-induced-cognitive-impairment-and-neuropathological-features-in-rat
#19
JOURNAL ARTICLE
Irena Majkutewicz, Ewelina Kurowska-Rucińska, Jan Ruciński, Dorota Myślińska, Beata Grembecka, Jagoda Mantej, Katarzyna P Dzik
Our previous study showed that dimethyl fumarate (DMF) treatment performed within three weeks after intracerebroventricular (ICV) injection of streptozotocin (STZ) attenuated spatial memory impairment, hippocampal neurodegeneration, and neuroinflammation in rats. The present study is aimed at verifying the hypothesis that DMF alleviates late effects of STZ (6 months after ICV injection) which reflects advanced stage of the Alzheimer's disease (AD) in human patients. Spatial memory was assessed with Morris water maze (MWM), general brain level of amyloid β (Aβ) and p-tau was measured by western blot, immunofluorescent labelling of active microglia (IBA1), Aβ and p-tau and histological assay of neurodegeneration (Fluoro-Jade C) were performed in hippocampus and cortex...
March 2, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38427255/promises-of-lipid-based-nanocarriers-for-delivery-of-dimethyl-fumarate-to-multiple-sclerosis-brain
#20
JOURNAL ARTICLE
Sreya Subhash, Nishtha Chaurawal, Kaisar Raza
Multiple sclerosis (MS) is a neurodegenerative autoimmune disorder of the central nervous system (CNS) infecting 2.5 million people worldwide. It is the most common nontraumatic neurological impairment in young adults. The blood-brain barrier rupture for multiple sclerosis pathogenesis has two effects: first, during the onset of the immunological attack, and second, for the CNS self-sustained "inside-out" demyelination and neurodegeneration processes. In addition to genetic variations, environmental and lifestyle variables can also significantly increase the risk of developing MS...
2024: Methods in Molecular Biology
keyword
keyword
53593
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.